Catalog No.S4274

For research use only.

Rotigotine is a dopamine receptor agonist, used in the treatment of Parkinson's disease and restless legs syndrome.

Rotigotine Chemical Structure

CAS No. 99755-59-6

Selleck's Rotigotine has been cited by 1 Publication

Purity & Quality Control

Choose Selective Dopamine Receptor Inhibitors

Other Dopamine Receptor Products

Biological Activity

Description Rotigotine is a dopamine receptor agonist, used in the treatment of Parkinson's disease and restless legs syndrome.
Dopamine receptor [1]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 63 mg/mL
(199.7 mM)
Ethanol 63 mg/mL
(199.7 mM)
Water Insoluble

Chemical Information

Molecular Weight 315.47


CAS No. 99755-59-6
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02728947 Completed Drug: ROTIGOTINE Parkinson''s Disease Luye Pharma Group Ltd. May 2016 Phase 1
NCT02070796 Completed Drug: Rotigotine PR2.2.1|Drug: Rotigotine PR2.1.1 Healthy UCB Pharma SA|UCB Pharma February 2014 Phase 1
NCT01675024 Completed Drug: Rotigotine Period 1|Drug: Rotigotine Period 2 Healthy UCB Pharma August 2012 Phase 1
NCT02786667 Unknown status Drug: Rotigotine|Drug: Placebo Parkinson Disease|Apathy University Hospital Grenoble June 2012 Phase 3
NCT01565018 Completed Drug: Rotigotine PR 2.1.4|Drug: Rotigotine PR 2.2.1 Healthy Volunteers UCB Pharma|Otsuka Pharmaceutical Co. Ltd. March 2012 Phase 1
NCT01536015 Terminated Drug: Rotigotine|Drug: Placebo Advanced Parkinson''s Disease UCB Pharma January 2012 Phase 3

(data from, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Rotigotine | Rotigotine ic50 | Rotigotine price | Rotigotine cost | Rotigotine solubility dmso | Rotigotine purchase | Rotigotine manufacturer | Rotigotine research buy | Rotigotine order | Rotigotine mouse | Rotigotine chemical structure | Rotigotine mw | Rotigotine molecular weight | Rotigotine datasheet | Rotigotine supplier | Rotigotine in vitro | Rotigotine cell line | Rotigotine concentration | Rotigotine nmr